BlackRock
MIST icon

BlackRock’s Milestone Pharmaceuticals MIST Stock Holding History

BlackRock’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,050,686
Closed -$9.56M – 5484
2024
Q4 		$9.56M Sell
4,050,686
-920,658
-19% -$1.58M ﹤0.01% 3459
2024
Q3 		$7.56M Hold
4,971,344
– – ﹤0.01% 3548
2024
Q2 		$6.56M Hold
4,971,344
– – ﹤0.01% 3583
2024
Q1 		$8.9M Buy
4,971,344
+1,700,595
+52% +$2.76M ﹤0.01% 3399
2023
Q4 		$5.46M Buy
3,270,749
+490,009
+18% +$1.33M ﹤0.01% 3656
2023
Q3 		$8.62M Buy
2,780,740
+129,540
+5% +$403K ﹤0.01% 3423
2023
Q2 		$7.56M Buy
2,651,200
+576,842
+28% +$2.18M ﹤0.01% 3549
2023
Q1 		$8.17M Buy
2,074,358
+346,529
+20% +$1.27M ﹤0.01% 3424
2022
Q4 		$6.84M Buy
1,727,829
+1,727,824
+34,556,480% +$9.1M ﹤0.01% 3569
2022
Q3 		$0 Buy
+5
New +$38 ﹤0.01% 5880
2020
Q3 		– Sell
-4,717
Closed -$18K – 5118
2020
Q2 		$18K Sell
4,717
-6,899
-59% -$22.2K ﹤0.01% 4714
2020
Q1 		$21K Buy
+11,616
New +$201K ﹤0.01% 4615

Other funds holding MIST

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock's MIST Position: Q1 2025 in Review

BlackRock sold out of Milestone Pharmaceuticals (MIST) in Q1 2025, closing a stake of 4,050,686 shares — an estimated $9.56M sold.

BlackRock first reported a position in MIST in Q1 2020 and held it in 12 quarters. The position peaked at $9.56M in Q4 2024. 43 funds tracked by Wall St. Rank hold MIST as of Q1 2025.

  • BlackRock reported no remaining Milestone Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • BlackRock sold 4,050,686 Milestone Pharmaceuticals shares in Q1 2025, an estimated $9.56M.
  • BlackRock first reported a position in Milestone Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • BlackRock's Milestone Pharmaceuticals position peaked at $9.56M in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2025.

Based on BlackRock's 13F filing for Q1 2025, filed 2 May 2025.